Article
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.
Blood advances - 8 Mar 2022
Fobare Sydney, Kohlschmidt Jessica, Ozer Hatice Gulcin, Mrózek Krzysztof, Nicolet Deedra, Mims Alice S, Garzon Ramiro, Blachly James S, Orwick Shelley, Carroll Andrew J, Stone Richard M, Wang Eunice S, Kolitz Jonathan E, Powell Bayard L, Oakes Christopher C, Eisfeld Ann-Kathrin, Hertlein Erin, Byrd John C
Abstract excerpt
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosine phosphatase non-receptor type 11 (PTPN11). The broader clinical implications of PTPN11 mutations in AML are still not well understood. The objective of this study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.